CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • RSLS Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • Community Annotations

ReShape Lifesciences (RSLS)

Company Profile
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.
ReShape Lifesciences logo

Company profile

Ticker
RSLS
Exchange
NASDAQ
Website
www.reshapelifesciences.com
CEO
Andrew Rasdal
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Surgical and Medical Instrument Manufacturing
Industry (SIC)
Surgical & Medical Instruments & Apparatus
Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • 3M • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
OBALON THERAPEUTICS INC
SEC CIK
0001427570
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
ReShape Weightloss, Inc. • ReShape Lifesciences Netherlands B.V. • ReShape Lifesciences Australia Pty Ltd • ReShape Costa Rica Sociedad de Responsabilidad Limited • Obalon Center for Weight Loss, Inc. ...

RSLS stock data

Latest filings (excl ownership)
View all
424B4
Prospectus supplement with pricing info
8 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
S-1MEF
Registration of additional securities for an S-1
3 Feb 23
S-1/A
IPO registration (amended)
3 Feb 23
RW WD
Withdrawal of registration withdrawal request
2 Feb 23
RW
Registration withdrawal request
2 Feb 23
RW
Registration withdrawal request
2 Feb 23
S-1/A
IPO registration (amended)
1 Feb 23
8-K
Other Events
27 Jan 23
S-1/A
IPO registration (amended)
26 Jan 23
Transcripts
View all
RSLS
Earnings call transcript
2022 Q3
14 Nov 22
RSLS
Earnings call transcript
2022 Q2
16 Aug 22
RSLS
Earnings call transcript
2019 Q4
29 Feb 20
RSLS
Earnings call transcript
2019 Q3
8 Nov 19
RSLS
Earnings call transcript
2019 Q2
24 Jul 19
RSLS
Earnings call transcript
2018 Q4
22 Feb 19
RSLS
Earnings call transcript
2018 Q3
2 Nov 18
RSLS
Earnings call transcript
2018 Q2
4 Aug 18
RSLS
Earnings call transcript
2018 Q1
12 May 18
RSLS
Earnings call transcript
2017 Q4
6 Mar 18
Latest ownership filings
View all
4
THOMAS STANKOVICH
20 Dec 22
4
THOMAS STANKOVICH
10 Nov 22
4
THOMAS STANKOVICH
6 Oct 22
4
THOMAS STANKOVICH
12 Sep 22
3
Paul F. Hickey
26 Aug 22
4
THOMAS STANKOVICH
11 Aug 22
4
Barton P. Bandy
11 Aug 22
4
THOMAS STANKOVICH
6 Jul 22
4
Barton P. Bandy
6 Jul 22
4
Barton P. Bandy
6 Jun 22

Financial summary

Financial statements Chart RSLS financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 6.25 mm 6.25 mm 6.25 mm 6.25 mm 6.25 mm 6.25 mm
Cash burn (monthly) 1.77 mm 1.92 mm 4.06 mm 5.48 mm 1.76 mm 1.87 mm
Cash used (since last report) 7.68 mm 8.35 mm 17.65 mm 23.83 mm 7.64 mm 8.16 mm
Cash remaining -1.44 mm -2.11 mm -11.41 mm -17.58 mm -1.40 mm -1.91 mm
Runway (months of cash) -0.8 -1.1 -2.8 -3.2 -0.8 -1.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2022

RSLS institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 21 19 +10.5%
Opened positions 5 4 +25.0%
Closed positions 3 3 –
Increased positions 4 2 +100.0%
Reduced positions 3 5 -40.0%
13F shares Current Prev Q Change
Total value 755.00 k 1.46 mm -48.3%
Total shares 1.36 mm 1.30 mm +4.7%
Total puts 0.00 0.00
Total calls 0.00 0.00
Total put/call ratio – – –
Largest owners Shares Value Change
Vanguard 503.62 k $290.00 k 0.0%
Geode Capital Management 297.86 k $171.00 k +6.1%
T. Rowe Price 170.90 k $99.00 k 0.0%
Armistice Capital 142.99 k $82.00 k NEW
Domain Parters Vii L P 62.50 k $0.00 0.0%
Renaissance Technologies 44.70 k $26.00 k NEW
NTRS Northern Trust 33.43 k $19.00 k 0.0%
Virtu Financial 25.58 k $15.00 k +141.7%
Citadel Advisors 21.55 k $12.00 k -33.8%
STT State Street 20.70 k $12.00 k 0.0%
Largest transactions Shares Bought/sold Change
Armistice Capital 142.99 k +142.99 k NEW
Susquehanna Fundamental Investments 0.00 -120.70 k EXIT
Renaissance Technologies 44.70 k +44.70 k NEW
Gsa Capital Partners 0.00 -36.49 k EXIT
Two Sigma Securities 19.43 k +19.43 k NEW
Geode Capital Management 297.86 k +17.23 k +6.1%
Virtu Financial 25.58 k +15.00 k +141.7%
Citadel Advisors 21.55 k -11.02 k -33.8%
Susquehanna International 0.00 -10.51 k EXIT
UBS UBS Group AG - Registered Shares 6.01 k +4.34 k +259.7%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RSLS insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Dec 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.1509 2,213 333.94 325,404
1 Dec 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.1513 5,144 778.29 327,617
28 Nov 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.1695 364,756 61.83 k 332,761
17 Nov 22 Thomas Stankovich Common Stock, $0.001 par value per share Grant Acquire A No No 0 364,756 0.00 697,517
4 Nov 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.2724 2,510 683.72 332,761
4 Nov 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.2725 5,883 1.60 k 335,271
4 Oct 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.2812 2,484 698.50 338,670
4 Oct 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.2807 5,809 1.63 k 341,154
6 Sep 22 Thomas Stankovich Common Stock, $0.001 par value per share Sell Dispose S No No 0.39 4,828 1.88 k 346,963
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 Feb 23
ReShape Lifesciences Announces Closing of Upsized $10.2M Underwritten Public Offering; Shares Spike Higher
8 Feb 23
ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwritten public offering of 1,275,000 units, with each
Nasdaq Down Over 100 Points; Tyson Foods Posts Downbeat Earnings
6 Feb 23
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 80 points on Monday. The Dow traded down 0.15% to 33,875.74 while the NASDAQ fell 0.88% to 11,900.97. The S&P 500 also fell, dropping, 0.59% to 4,112.13.
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
6 Feb 23
Crude Oil Down Over 1%; Nasdaq Drops 80 Points
6 Feb 23

Press releases

From Benzinga Pro
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
8 Feb 23
SAN CLEMENTE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
6 Feb 23
SAN CLEMENTE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized
Thinking about buying stock in ReShape Lifesciences, Exicure, Blue Apron, Coherus Biosciences, or Icecure Medical?
23 Dec 22
NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RSLS, XCUR, APRN, CHRS, and ICCM.
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
22 Dec 22
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 Nov 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn